17α-Hydroxyprogesterone Caproate Access in the Louisiana Medicaid Population

Abstract Preterm birth and its associated neonatal morbidities remain pertinent health care and economic issues in the United States. Progesterone supplementation in the form of 17α-hydroxyprogesterone caproate has been reported to reduce the risk for recurrent preterm birth in women with a prior sp...

Full description

Saved in:
Bibliographic Details
Published in:Clinical therapeutics 2015-04, Vol.37 (4), p.727-732
Main Authors: Orsulak, Mary Kathryn, MSc, Block-Abraham, Dana, DO, Gee, Rebekah E., MD, MPH
Format: Article
Language:English
Subjects:
17α-hydroxyprogesterone caproate
Adult
Affordable Care Act
Drug Administration Schedule
Female
Health Services Accessibility - economics
Health Services Accessibility - statistics & numerical data
Humans
Hydroxyprogesterones - administration & dosage
Hydroxyprogesterones - economics
Hydroxyprogesterones - supply & distribution
Infant, Newborn
Insurance Coverage
Internal Medicine
Louisiana
Medicaid
Medicaid - economics
Medical Education
Patient Protection and Affordable Care Act - economics
Pregnancy
Premature Birth - economics
Premature Birth - prevention & control
Prenatal Care - economics
Prenatal Care - utilization
progesterone
Recurrence
Reimbursement, Incentive
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Preterm birth and its associated neonatal morbidities remain pertinent health care and economic issues in the United States. Progesterone supplementation in the form of 17α-hydroxyprogesterone caproate has been reported to reduce the risk for recurrent preterm birth in women with a prior spontaneous preterm delivery, but several barriers contribute to its underutilization. The Affordable Care Act has increased the number of women receiving insurance coverage for pre- and perinatal care. However, the increase in insurance coverage has not necessarily facilitated access to standard therapies such as progesterone for the prevention of preterm birth. Data from Louisiana illustrate this point, and the state has responded by developing educational programs and the nation’s first pay-for-performance strategy targeting the initiation of progesterone therapy.
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2015.01.007